Progenics Collaborates with Veterans Affairs on AI Research Program for Medical Image Analysis

A close collaboration between the Veterans Affairs Greater Los Angeles Healthcare System (VAGLAHS) and Progenics Pharmaceuticals will focus on the development and validation of artificial intelligence (AI) algorithms in medical images for disease management for veterans with prostate cancer. “The promise of AI in healthcare, specifically in this collaboration, is to increase the quality of care while driving down costs,” said Aseem Anand, PhD, vice president and site manager of EXINI Diagnostics, in an interview with MD+DI. EXINI Diagnostics, recently acquired by Progenics, specializes in medical imaging AI and the development of validated imaging biomarkers and medical devices. Its main focus is to support Progenics’ pipeline of prostate-specific membrane antigen (PSMA)–imaging radiopharmaceuticals, Anand said. In the initial phases of the collaboration, the VAGLAHS network will gain access to Progenics’s machine-learning platforms—the automated Bone Scan Index (aBSI) technology and PSMA platform. The FDA-cleared aBSI technology gives a fully quantitative assessment of bone scans that incorporates inferred masses of all lesions. Anand explained that in a prospectively defined, multi-institutional, phase-three study with 721 metastatic prostate cancer patients, aBSI was found to be an independent prognostic determinant of overall survival. The s...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news